Argenica Therapeutics Ltd
ASX:AGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Greenply Industries Ltd
NSE:GREENPLY
|
IN |
Argenica Therapeutics Ltd
Income from Continuing Operations
Argenica Therapeutics Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Argenica Therapeutics Ltd
ASX:AGN
|
Income from Continuing Operations
-AU$7.2m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-80%
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Income from Continuing Operations
-AU$30.3m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Income from Continuing Operations
-AU$90.1m
|
CAGR 3-Years
26%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Income from Continuing Operations
AU$30.4m
|
CAGR 3-Years
449%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Income from Continuing Operations
-AU$64.3m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-56%
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Income from Continuing Operations
AU$10.4m
|
CAGR 3-Years
12%
|
CAGR 5-Years
12%
|
CAGR 10-Years
9%
|
|
Argenica Therapeutics Ltd
Glance View
Argenica Therapeutics Ltd. provides neuroprotective treatment. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2021-06-11. Argenica’s lead candidate, ARG-007, aims to protect brain cells and reduce cell death following a stroke, and other types of neural injury. Argenica has accumulated a comprehensive body of published pre-clinical studies demonstrating efficacy of ARG-007 in multiple models of stroke and other central nervous system injury models, including stroke, traumatic brain injury and perinatal hypoxia ischaemia.
See Also
What is Argenica Therapeutics Ltd's Income from Continuing Operations?
Income from Continuing Operations
-7.2m
AUD
Based on the financial report for Jun 30, 2025, Argenica Therapeutics Ltd's Income from Continuing Operations amounts to -7.2m AUD.
What is Argenica Therapeutics Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-80%
Over the last year, the Income from Continuing Operations growth was -31%. The average annual Income from Continuing Operations growth rates for Argenica Therapeutics Ltd have been -21% over the past three years , -80% over the past five years .
